L-GILZ binds p53 and MDM2 and suppresses tumor growth through p53 activation in human cancer cells

被引:0
|
作者
E Ayroldi
M G Petrillo
A Bastianelli
M C Marchetti
S Ronchetti
G Nocentini
L Ricciotti
L Cannarile
C Riccardi
机构
[1] Section of Pharmacology,Department Medicine
[2] University of Perugia Medical School,undefined
来源
Cell Death & Differentiation | 2015年 / 22卷
关键词
D O I
暂无
中图分类号
学科分类号
摘要
The transcription factor p53 regulates the expression of genes crucial for biological processes such as cell proliferation, metabolism, cell repair, senescence and apoptosis. Activation of p53 also suppresses neoplastic transformations, thereby inhibiting the growth of mutated and/or damaged cells. p53-binding proteins, such as mouse double minute 2 homolog (MDM2), inhibit p53 activation and thus regulate p53-mediated stress responses. Here, we found that long glucocorticoid-induced leucine zipper (L-GILZ), a recently identified isoform of GILZ, activates p53 and that the overexpression of L-GILZ in p53+/+ HCT116 human colorectal carcinoma cells suppresses the growth of xenografts in mice. In the presence of both p53 and MDM2, L-GILZ binds preferentially to MDM2 and interferes with p53/MDM2 complex formation, making p53 available for downstream gene activation. Consistent with this finding, L-GILZ induced p21 and p53 upregulated modulator of apoptosis (PUMA) expression only in p53+/+ cells, while L-GILZ silencing reversed the anti-proliferative activity of dexamethasone as well as expression of p53, p21 and PUMA. Furthermore, L-GILZ stabilizes p53 proteins by decreasing p53 ubiquitination and increasing MDM2 ubiquitination. These findings reveal L-GILZ as a regulator of p53 and a candidate for new therapeutic anti-cancer strategies for tumors associated with p53 deregulation.
引用
收藏
页码:118 / 130
页数:12
相关论文
共 50 条
  • [11] P53 Mdm2 Inhibitors
    Khoury, Kareem
    Doemling, Alex
    CURRENT PHARMACEUTICAL DESIGN, 2012, 18 (30) : 4668 - 4678
  • [12] MDM2与p53
    金晶
    刘耕陶
    癌症, 2001, (06) : 663 - 666
  • [13] Immunoreactivity for p53 and mdm2 and the detection of p53 mutations in human malignant mesothelioma
    Segers, K
    Backhovens, H
    Kumar-Singh, S
    DeVoecht, J
    Ramael, M
    Van Broeckhoven, C
    VanMarck, E
    VIRCHOWS ARCHIV, 1995, 427 (04) : 431 - 436
  • [14] Ribosomal protein S7 as a novel modulator of p53–MDM2 interaction: binding to MDM2, stabilization of p53 protein, and activation of p53 function
    D Chen
    Z Zhang
    M Li
    W Wang
    Y Li
    E R Rayburn
    D L Hill
    H Wang
    R Zhang
    Oncogene, 2007, 26 : 5029 - 5037
  • [15] p53 inhibition by MDM2 in human pterygium
    Cao, Di
    Tsz Kin Ng
    Yip, Yolanda W. Y.
    Young, Alvin L.
    Pang, Chi Pui
    Chu, Wai Kit
    Jhanji, Vishal
    EXPERIMENTAL EYE RESEARCH, 2018, 175 : 142 - 147
  • [16] p53 and Mdm2: not all cells are equal
    Coates, P. J.
    JOURNAL OF PATHOLOGY, 2007, 213 (04): : 357 - 359
  • [17] Inorganic arsenic induces MDM2, p53, and their phosphorylation and affects the MDM2/p53 complex in vitro
    Yin, Jinyao
    Zhou, Qian
    Tan, Jingwen
    Che, Wangjun
    He, Yuefeng
    ENVIRONMENTAL SCIENCE AND POLLUTION RESEARCH, 2022, 29 (58) : 88078 - 88088
  • [18] Inorganic arsenic induces MDM2, p53, and their phosphorylation and affects the MDM2/p53 complex in vitro
    Jinyao Yin
    Qian Zhou
    Jingwen Tan
    Wangjun Che
    Yuefeng He
    Environmental Science and Pollution Research, 2022, 29 : 88078 - 88088
  • [19] P53 degradation by Mdm2 - A novel mechanism for regulation of p53 stability
    Nampoothiri, VK
    CURRENT SCIENCE, 1998, 75 (09): : 875 - 877
  • [20] p53 mRNA controls p53 activity by managing Mdm2 functions
    Marco M. Candeias
    Laurence Malbert-Colas
    Darren J. Powell
    Chrysoula Daskalogianni
    Magda M. Maslon
    Nadia Naski
    Karima Bourougaa
    Fabien Calvo
    Robin Fåhraeus
    Nature Cell Biology, 2008, 10 : 1098 - 1105